Vima Therapeutics Funding: $100M Raised, Series A (2025)
Vima Therapeutics is a Biotech company based in Cambridge, Massachusetts. It has raised $100M in total funding. Latest round: Series A.
Vima Therapeutics funding overview
Vima Therapeutics is a Biotech company based in Cambridge, Massachusetts. Vima Therapeutics has raised $100M in total disclosed funding. That places its disclosed total in the $100M–$250M range. Its most recent disclosed round is a Series A announced in May 2025. The round record for Vima Therapeutics runs through 2025; nothing later has been disclosed. Investors on record include Atlas Venture, Access Industries, Canaan Partners, Frazier Life Sciences. 4 distinct backers are named across the disclosed rounds.
Vima Therapeutics at a glance
Total raised
$100M
Latest round
Series A
Latest round date
May 2025
Industry
Biotech
Headquarters
Cambridge, Massachusetts
Notable investors
Atlas Venture, Access Industries, Canaan Partners, Frazier Life Sciences
Frequently asked about Vima Therapeutics funding
How much has Vima Therapeutics raised?
Vima Therapeutics has raised $100M in total disclosed funding across the rounds on record.
Who has invested in Vima Therapeutics?
Atlas Venture, Access Industries, Canaan Partners, Frazier Life Sciences are named among the investors backing Vima Therapeutics.
What was the latest Vima Therapeutics funding round?
The most recent disclosed round is a Series A, announced in May 2025.
Where is Vima Therapeutics based?
Vima Therapeutics is based in Cambridge, Massachusetts.
What sector does Vima Therapeutics operate in?
Vima Therapeutics is tracked under Biotech from Cambridge, Massachusetts, with $100M in disclosed funding.
When did Vima Therapeutics last raise?
The last disclosed Vima Therapeutics round closed in May 2025 at Series A.
Every Vima Therapeutics figure above comes from filings and announced rounds in the StartupFundraising company database and is revised as new rounds are recorded. The lists below compare Biotech companies in Cambridge at a similar stage.
